Therapeutic approaches for the modification of high-density lipoproteins

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 2, 2004, Pages 177-187

  von Eckardstein, Arnold ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ABC TRANSPORTER A1; ANTIOBESITY AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; BEZAFIBRATE; CHOLESTEROL; CHOLESTEROL ESTER; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FINGOLIMOD; GEMFIBROZIL; GLUTATHIONE PEROXIDASE; GUGGULSTERONE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; PIOGLITAZONE; PROBUCOL; RAGAGLITAZAR; RIMONABANT; ROSIGLITAZONE; UNINDEXED DRUG;

ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CHOLESTASIS; CLINICAL TRIAL; CORRELATION FUNCTION; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIPOPROTEIN METABOLISM; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MODULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; REGULATORY MECHANISM; SIDE EFFECT; STENOSIS; STENT; TREATMENT PLANNING;

EID: 13344268904     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.09.004     Document Type: Review

References (55)

1. M. Hersberger A. von Eckardstein Low high density lipoprotein cholesterol - physiological background, clinical importance and drug treatment Drugs 63 2003 1907-1945
2. A. von Eckardstein et al. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport Arterioscler. Thromb. Vasc. Biol. 21 2001 13-27
3. G.F. Watts et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome Diabetes 52 2003 803-811
4. S. Bilz et al. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia J. Lipid Res. 45 2004 174-185
5. C. Duval et al. The role of PPARs in atherosclerosis Trends Mol. Med. 9 2002 422-430
6. N. Marx et al. Peroxisome proliferator-activated receptors and atherogenesis: Regulators of gene expression in vascular cells Circ. Res. 94 2004 168-178
7. G. Martin et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I J. Clin. Invest. 107 2001 1423-1432
8. A. von Eckardstein G. Assmann Prevention of coronary heart disease by raising of HDL cholesterol? Curr. Opin. Lipidol. 11 2000 627-637
9. A.D. Mooradian et al. Transcriptional control of apolipoprotein A-I gene expression in diabetes Diabetes 53 2004 513-520
10. S. Lamon-Fava D. Micherone Regulation of apoA-I gene expression: mechanism of action of estrogen and genistein J. Lipid Res. 45 2004 106-112
11. F.K. Welty Alternative hormone replacement regimens: Is there a need for further clinical trials? Curr. Opin. Lipidol. 14 2003 585-591
12. T. Claudel et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element J. Clin. Invest. 109 2002 961-971
13. G.A. Kullak-Ublick et al. Enterohepatic bile salt transporters in normal physiology and liver disease Gastroenterology 126 2004 322-342
14. J. Cui et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump J. Biol. Chem. 278 2003 10214-10220
15. P.O. Szapary et al. Guggulipid for the treatment of hypercholesterolemia: A randomized controlled trial J. Am. Med. Assoc. 290 2003 765-772
16. R.R. Singaraja et al. Efflux and atherosclerosis: The clinical and biochemical impact of variations in the ABCA1 gene Arterioscler. Thromb. Vasc. Biol. 23 2003 1322-1332
17. C. Joyce et al. Study of ABCA1 function in transgenic mice Arterioscler. Thromb. Vasc. Biol. 23 2003 965-971
18. N. Wang A.R. Tall Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux Arterioscler. Thromb. Vasc. Biol. 23 2003 1178-1184
19. P. Costet et al. Retinoic acid receptor-mediated induction of ABCA1 in macrophages Mol. Cell. Biol. 23 2003 7756-7766
20. P. Tontonoz D.J. Mangelsdorf Liver X receptor signaling pathways in cardiovascular disease Mol. Endocrinol. 17 2003 985-993
21. B. Haidar et al. Apolipoprotein. A-I activates cellular cAMP signaling through the ABCA1 transporter J. Biol. Chem. 279 2004 9963-9969
22. G. Lin K.E. Bornfeldt Cyclic AMP-specific phosphodiesterase 4 inhibitors promote ABCA1 expression and cholesterol efflux Biochem. Biophys. Res. Commun. 290 2002 663-669
23. T. Rubic et al. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin Biochem. Pharmacol. 67 2004 411-419
24. L.O. Martinez et al. Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I J. Biol. Chem. 278 2003 37368-37374
25. Y. Yamauchi et al. Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly J. Biol. Chem. 278 2003 47890-47897
26. J.R. Nofer et al. Involvement of Cdc42 signaling in apoA-I-induced cholesterol efflux J. Biol. Chem. 278 2003 53055-53062
27. P.J. Barter et al. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis Arterioscler. Thromb. Vasc. Biol. 23 2003 160-167
28. G.J. de Grooth et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: A randomized phase II dose-response study Circulation 105 2002 2159-2165
29. R.W. Clark et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib Arterioscler. Thromb. Vasc. Biol. 24 2004 490-497
30. M.E. Brousseau et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N. Engl. J. Med. 350 2004 1505-1515
31. H. Okamoto et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits Nature 406 2000 203-207
32. Z. Huang et al. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia Clin. Sci. (Lond.) 103 2002 587-594
33. B.L. Trigatti et al. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis Arterioscler. Thromb. Vasc. Biol. 23 2003 1732-1738
34. C. Mineo P.W. Shaul HDL stimulation of endothelial nitric oxide synthase: A novel mechanism of HDL action Trends Cardiovasc. Med. 13 2003 226-231
35. C. Langer et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages Biochem. Biophys. Res. Commun. 296 2002 1051-1057
36. F.C.W. Wu A. von Eckardstein Androgens and coronary artery disease Endocrine Rev 24 2003 183-217
37. F. Rinninger et al. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism Arterioscler. Thromb. Vasc. Biol. 19 1999 1325-1332
38. L.E. Spieker et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men Circulation 105 2002 1399-1402
39. R.J. Bisoendial et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein Circulation 107 2003 2944-2948
40. G. Chiesa C.R. Sirtori Apolipoprotein A-I(Milano): Current perspectives Curr. Opin. Lipidol. 14 2003 159-163
41. S. Kaul et al. Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries Circulation 107 2003 2551-2554
42. S.E. Nissen et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial J. Am. Med. Assoc. 290 2003 2292-2300
43. M. Navab et al. Oral administration of an Apo A-I mimetic peptide synthesized from d -amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol Circulation 105 2002 290-292
44. M. Navab et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice Circulation 109 2004 3215-3220
45. J.R. Nofer et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3 J. Clin. Invest. 113 2004 569-581
46. L. Rohrer et al. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease Curr. Opin. Lipidol. 15 2004 269-278
47. V. Brinkmann et al. FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function Am. J. Transplant. 4 2004 1019-1025
48. M.F. Saad et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: A 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm Diabetes Care 27 2004 1324-1329
49. R. Chakrabarti et al. Antidiabetic and hypolipidemic potential of DRF 2519-a dual activator of PPAR-alpha and PPAR-gamma Eur. J. Pharmacol. 491 2004 195-206
50. T.W. Doebber et al. MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities Biochem. Biophys. Res. Commun. 318 2004 323-328
51. B.D. Hegarty et al. peroxisome proliferator-activated receptor (ppar) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo - a study using the Novel PPAR alpha/gamma Agonist Tesaglitazar Endocrinology 145 2004 3158-3164
52. G. Schmitz et al. Zinc finger protein ZNF202 structure and function in transcriptional control of HDL metabolism Curr. Opin. Lipidol. 15 2004 199-208
53. J.C. Clapham Treating obesity: Pharmacology of energy expenditure Curr. Drug Targets 5 2004 309-323
54. J.R. Fernandez D.B. Allison Rimonabant Sanofi-Synthelabo Curr. Opin. Investig. Drugs 5 2004 430-435
55. J.G. Cleland et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure Eur. J. Heart Fail. 6 2004 501-508